Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis

Company Overview

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.56 to $1.42
• 52-Week Range: N/A
• Volume: 1,375 shs
• Average Volume: 525,982 shs
• Market Capitalization: $8 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

INNT Stock Analysis - Frequently Asked Questions

How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) issued its quarterly earnings data on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11).

What other stocks do shareholders of Innovate Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Innovate Biopharmaceuticals investors own include 9 Meters Biopharma (NMTR), NIO (NIO), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET), Iterum Therapeutics (ITRM), Meta Platforms (META) and Micron Technology (MU).

Company Calendar

• Last Earnings: 3/18/2019
• Today: 7/14/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:INNT
• CIK: 1551986
• Web: www.innovatebiopharma.com
• Phone: 919-275-1933
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$27.05 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -234.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.35
• Quick Ratio: 0.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.27) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 41,325,000
• Free Float: N/A
• Market Cap: $8 thousand
• Optionable: Not Optionable
• Beta: -0.39